Clinical outcomes of Estonian patients with primary multidrug-resistant versus drug-susceptible tuberculosis

被引:35
作者
Lockman, S
Kruuner, A
Binkin, NJ
Levina, K
Wang, YC
Danilovitsh, M
Hoffner, SE
Tappero, HW
机构
[1] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Epidemiol Program Off, Atlanta, GA 30333 USA
[2] Natl Ctr HIV AIDS STD & TB Prevent, Div TB Eliminat, Atlanta, GA USA
[3] Univ Tartu, Lung Hosp, EE-50090 Tartu, Estonia
[4] Kivimae Hosp, Tallinn, Estonia
[5] Swedish Inst Infect Dis, Stockholm, Sweden
关键词
D O I
10.1086/318489
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Little is known about the clinical outcomes of patients with primary multidrug-resistant (MDR) tuberculosis. Clinical outcomes among 46 patients in Estonia with primary MDR tuberculosis and 46 patients with pan-susceptible tuberculosis were compared. Patients with MDR tuberculosis were more likely than those with pansensitive tuberculosis to have treatment failure (odds ratio, 8.9; 95% confidence interval [CI], 3.0-26.3) after adjusting for medical problems and weeks of effective treatment, often with second-line drugs. Ten patients (22%) with MDR tuberculosis and 2 (4%) with susceptible tuberculosis died of tuberculosis (P = .03). MDR tuberculosis (hazard ratio [HR], 7.8; 95% CI, 1.6- 37.4), number of medical problems (HR, 2.5;.03 95% CI, 1.5- 4.4), and male sex (HR, 5.8; 95% CI, 1.1- 29.6) were associated with death due to tuberculosis in multivariable analysis. Human immunodeficiency virus test results were negative for all 55 patients tested. These findings underscore the urgent need for increased attention to prevention and treatment of MDR tuberculosis globally.
引用
收藏
页码:373 / 380
页数:8
相关论文
共 31 条
[1]  
[Anonymous], MORBIDITY MORTALITY
[2]  
CANETTI G, 1969, B WORLD HEALTH ORGAN, V41, P21
[3]  
*CDC, 1987, MMWR-MORBID MORTAL W, V35, P785
[4]  
*CDCP, 1996, MMWR-MORBID MORTAL W, V45, P330
[5]  
*CDCP, 1991, MMWR-MORBID MORTAL W, V40, P129
[6]  
Centers for Disease Control (CDC), 1990, MMWR Morb Mortal Wkly Rep, V39, P369
[7]   Drug-resistant tuberculosis: Review of the worldwide situation and the WHO/IUATLD global surveillance project [J].
Cohn, DL ;
Bustreo, F ;
Raviglione, MC .
CLINICAL INFECTIOUS DISEASES, 1997, 24 :S121-S130
[8]   TRANSMISSION OF MULTIDRUG-RESISTANT MYCOBACTERIUM-TUBERCULOSIS AMONG PERSONS WITH HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION IN AN URBAN HOSPITAL - EPIDEMIOLOGIC AND RESTRICTION-FRAGMENT-LENGTH-POLYMORPHISM ANALYSIS [J].
CORONADO, VG ;
BECKSAGUE, CM ;
HUTTON, MD ;
DAVIS, BJ ;
NICHOLAS, P ;
VILLAREAL, C ;
WOODLEY, CL ;
KILBURN, JO ;
CRAWFORD, JT ;
FRIEDEN, TR ;
SINKOWITZ, RL ;
JARVIS, WR .
JOURNAL OF INFECTIOUS DISEASES, 1993, 168 (04) :1052-1055
[9]  
Enarson DA, 1996, TUBERCULOSIS GUIDE L
[10]   CLINICAL PRESENTATION AND OUTCOME OF PATIENTS WITH HIV-INFECTION AND TUBERCULOSIS CAUSED BY MULTIPLE-DRUG-RESISTANT BACILLI [J].
FISCHL, MA ;
DAIKOS, GL ;
UTTAMCHANDANI, RB ;
POBLETE, RB ;
MORENO, JN ;
REYES, RR ;
BOOTA, AM ;
THOMPSON, LM ;
CLEARY, TJ ;
OLDHAM, SA ;
SALDANA, MJ ;
LAI, SH .
ANNALS OF INTERNAL MEDICINE, 1992, 117 (03) :184-190